跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 78 条关于
“AL101/GSK4527226”
全部
78
临床试验
42
药物
17
机构
0
资讯
19
去年
Alector Announces Strategic Priorities for 2025, Highlights Neurodegenerative Disease Programs
10个月前
Alector's Late-Stage Frontotemporal Dementia Drug Fails Phase III Trial, Company Cuts Workforce by 49%
去年
Alector's Phase 3 FTD Trial Misses Primary Endpoint Despite FDA-Endorsed Statistical Plan Amendment
11个月前
Alector's Latozinemab Fails Phase III Trial for Frontotemporal Dementia, Company Cuts Workforce by Half
去年
Alector's AL002 Fails to Meet Primary Endpoint in Phase 2 Alzheimer's Trial
去年
Calluna Pharma's CAL101 Demonstrates Favorable Safety Profile in Phase I Trial for Fibrotic Diseases
去年
Calluna Pharma Appoints Mark Gaffney as CEO, Advances CAL101 Program
去年
Alzamend Neuro's AL001 Identifies Tolerable Dosage in Alzheimer's Therapy Trial
去年
Alzamend Neuro Regains Nasdaq Compliance, Plans Phase II Trials for AL001
10个月前
Alzamend Neuro Completes Phase II Brain Imaging Study of Novel Lithium Therapy AL001
第 1 页,共 2 页
上一页
下一页